Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-7-[4-[2-(4-Fluorophenyl)Acetyl]-1-Piperazinyl]-1,4-Dihydro-4-Oxo- is a high-purity, advanced pharmaceutical intermediate of significant commercial and research interest. This compound is a key synthetic precursor in the development of novel fluoroquinolone antibiotics, valued for its precise molecular architecture that enables targeted pharmacological activity. It is primarily required by pharmaceutical R&D laboratories, fine chemical manufacturers, and contract development and manufacturing organizations (CDMOs) engaged in the synthesis of next-generation antibacterial agents.

Application

• Pharmaceutical Intermediate: Critical building block in the synthesis of novel fluoroquinolone-class antibiotics.
• Active Pharmaceutical Ingredient (API) Development: Used in research and process development for new antibacterial drug candidates.
• Chemical Synthesis Research: Serves as a model compound in medicinal chemistry for studying structure-activity relationships (SAR) in quinolone derivatives.
• Contract Manufacturing: Supplied to CDMOs for scale-up and cGMP production of proprietary drug substances.
• Reference Standard: Utilized as a high-purity analytical standard for quality control and regulatory submissions.
• Biochemical Research: Investigated for its interaction with bacterial DNA gyrase and topoisomerase IV enzymes.

Basic Information

Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-Fluoro-7-[4-[2-(4-Fluorophenyl)Acetyl]-1-Piperazinyl]-1,4-Dihydro-4-Oxo-
CAS No.	1054128-95-8
Molecular Formula	C24H21F2N3O4
Molecular Weight	453.44 g/mol
Synonyms	1-Cyclopropyl-6-fluoro-7-[4-[2-(4-fluorophenyl)acetyl]piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; WCK 771 Intermediate; 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-(2-(4-fluorophenyl)acetyl)piperazin-1-yl)quinoline-3-carboxylic acid; (1-Cyclopropyl-6-fluoro-4-oxo-7-(4-(2-(4-fluorophenyl)acetyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid); WCK-771 (Intermediate); Levonadifloxacin Intermediate; Nadifloxacin Derivative Intermediate
EINECS	Contact for details

Quality Control

Our 3-Quinolinecarboxylic Acid derivative is manufactured under strict quality management systems. Every batch undergoes rigorous analytical testing, including HPLC for purity, NMR and IR for structural confirmation, and stringent control of residual solvents and impurities to meet pharmaceutical intermediate standards. Comprehensive Certificates of Analysis (COA) detailing all specifications are provided to ensure traceability and compliance with your R&D and regulatory requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and light-sensitive; therefore, containers must be kept tightly sealed and under an inert atmosphere if necessary to prevent degradation.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Any single impurity ≤ 0.5%, Total impurities ≤ 2.0%
Water Content (KF)	≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.